^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Peripheral T-cell Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    LB-100 (PP2A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2023
    Title:

    PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB

    Published date:
    05/11/2023
    Excerpt:
    In this study, we applied PP2A inhibitor LB100 in combination with crizotinib to normal ALCL cell lines....LB100 significantly enhanced the killing effect of crizotinib in normal tumor cell lines and partially reversed crizotinib resistance in resistant lines. Western blot and immunofluorescence experiments showed that LB100 leads to increased cellular G1 phase block by increasing cellular DNA damage, which in turn enhances the sensitivity of crizotinib....In conclusion, LB100, as an effective inhibitor of PP2A, can significantly increase the effect of crizotinib against normal NPM-ALK+ ALCL, inhibit the growth of crizotinib-resistant strains, and partially restore the sensitivity of crizotinib...